Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders-Reference-Cited by-同舟云学术

Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders

Published:2018-03-02 Issue:6 Volume:235 Page:1697-1709
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Khoja Sheraz^ORCID,Huynh Nhat,Warnecke Alicia M. P.,Asatryan Liana,Jakowec Michael W.,Davies Daryl L.

Funder

National Institute on Alcohol Abuse and Alcoholism

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/article/10.1007/s00213-018-4869-9/fulltext.html

Reference127 articles.

1. Amadio S, Montilli C, Picconi B, Calabrei P, Volont C (2007) Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: an immunohistological study. Purinergic Signal 3:389–398

2. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21:72–77

3. Arena JP, Liu KK, Paress PS, Cully DF (1991) Avermectin-sensitive chloride currents induced by Caenorhabditis elegans RNA in Xenopus oocytes. Mol Pharmacol 40:368–374

4. Arena JP, Liu KK, Paress PS, Schaeffer JM, Cully DF (1992) Expression of a glutamate-activated chloride current in Xenopus oocytes injected with Caenorhabditis elegans RNA: evidence for modulation by avermectin. Brain Res Mol Brain Res 15:339–348

5. Arena JP, Liu KK, Paress PS, Frazier EG, Cully DF, Mrozik H, Schaeffer JM (1995) The mechanism of action of avermectins in Caenorhabditis elegans: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity. J Parasitol 81:286–294

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder;Expert Opinion on Emerging Drugs;2024-04-18

2. Ivermectin increases striatal cholinergic activity to facilitate dopamine terminal function;Cell & Bioscience;2024-04-17

3. Ivermectin increases striatal cholinergic activity to facilitate dopamine terminal function;2023-12-03

4. Forging Ahead the Repositioning of Multitargeted Drug Ivermectin;Current Drug Delivery;2023-10

5. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions;Journal of Pharmacological Sciences;2023-05